Humanised antibodies are developed using advances in recombinant DNA technology. They are essentially mouse antibodies that have been modified to carry a few human segments. Due to this genetic alteration, they are often referred to as chimeric antibodies.

These antibodies are medically significant because they possess higher effectiveness and activity. By incorporating human segments, they function similarly to natural human proteins, which ensures they do not induce unwanted immune responses or allergic reactions. Consequently, they serve as efficient therapeutic agents and can be coupled with toxins or drugs for targeted action against specific tissues.